hotspot -WSS

hotspot

author：leisure time 2025-10-02 19:19:40 - browse：97

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： How the political right came to back psychedelics to treat trauma

focus

WSS

HCA discloses massive data breach affecting 11 million patients

Hospitals look to new technology to keep health care workers safe

What to know about OceanGate, the company behind the missing Titanic submersible

Study: Pain burden is higher in Black NFL players than white ones

NYU radiologists take on the challenge of expensive MRI machines

How the political right came to back psychedelics to treat trauma

focus

hotspot

Bluebird and the case for gene therapy profits

entertainment

Affirmative action in medical school literally saved lives

Morphosys mixed study results for blood cancer drug

New air purifier tech could be key to improving indoor air quality

Lecanemab for Alzheimer's is coming. Is the health system ready?

Activists slam private health insurers over coverage restrictions

Living with Fabry disease, a condition that causes chronic pain

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

ChatGPT in medicine: STAT answers readers' burning questions

Wegovy, Zepbound and weight loss drugs that preserve muscle

Wikipedia

FDA's Woodcock to retire early next year

PBM reforms clear House panel

In key trial, Verve's treatment lowers cholesterol levels in patients

HCA discloses massive data breach affecting 11 million patients

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

focus

focus

focus

focus